|
|
|
|
|
| Santos,Mariana Lopes dos; Quintilio,Wagner; Manieri,Tania Maria; Tsuruta,Lilian Rumi; Moro,Ana Maria. |
| The use of serum containing polyclonal antibodies from animals immunized with toxins marked the beginning of the application of antibody-based therapy in late nineteenth century. Advances in basic research led to the development of the hybridoma technology in 1975. Eleven years later, the first therapeutic monoclonal antibody (mAb) was approved, and since then, driven by technological advances, the development of mAbs has played a prominent role in the pharmaceutical industry. In this review, we present the developments to circumvent problems of safety and efficacy arising from the murine origin of the first mAbs and generate structures more similar to human antibodies. As of October 2017, there are 61 mAbs and 11 Fc-fusion proteins in clinical use. An... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Immunotherapy; CDR grafting; Phage display; Transgenic mice; Single B cell sorting.. |
| Ano: 2018 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502018000700406 |
| |
|
|
| Yu-bao,Cui; Zhou,Ying; Weihong,Shi; Guifang,Ma; Yang,Li; Yungang,Wang. |
| To obtain the recombinant group 2 allergen product of Dermatophagoides farinae (Der f 2), the Der f 2 gene was synthesized by RT-PCR. The full-length cDNA comprised 441 nucleotides and was 99.3% identical to the reference sequence (GenBank AB195580). The cDNA was bound to vector pET28a to construct plasmid pET28a(+)-Der f 2, which was transformed into E. coli BL21 and induced by IPTG. SDS-PAGE showed a specific band of about 14kDa in the hole cell lysate. s estiated by chroatography, about 3.86 g of the recobinant product as obtained, which conjugated with serum IgE from asthmatic children. The protein had a signal peptide of 17 amino acids. Its secondary structure comprised an alpha helix (19.86%), an extended strand (30.82%), and a random coil (49.32%).... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Dermatophagoides farinae; House-dust-mite allergy; Mite allergens; Der f 2; Allergen engineering; Immunotherapy; Bioinformatics. |
| Ano: 2010 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652010000400017 |
| |
|
|
| Zheng,Jin; Liu,Qiang; Yang,Jiandong; Ren,Qinyou; Cao,Wei; Yang,Jingyue; Yu,Zhaocai; Yu,Fang; Wu,Yanlan; Shi,Hengjun; Liu,Wenchao. |
| A dendritic cell (DC)-based vaccine strategy could reduce the risk of recurrence and improve the survival of breast cancer patients. However, while therapy-induced apoptosis of hepatocellular and colorectal carcinoma cells can enhance maturation and antigen presentation of DCs, whether this effect occurs in breast cancer is currently unknown. In the present study, we investigated the effect of doxorubicin (ADM)-induced apoptotic MCF-7 breast cancer cells on the activation of DCs. ADM-induced apoptotic MCF-7 cells could effectively induce immature DC (iDC) maturation. The mean fluorescence intensity (MFI) of DC maturity marker CD83 was 23.3 in the ADM-induced apoptotic MCF-7 cell group compared with 8.5 in the MCF-7 cell group. The MFI of DC co-stimulatory... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Breast cancer; Dendritic cells; Immunotherapy; Apoptosis; Doxorubicin. |
| Ano: 2012 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2012000600006 |
| |
|
| |
|
|
| Yuan,J.L.; Wang,F.L.; Yi,X.M.; Qin,W.J.; Wu,G.J.; Huan,Y.; Yang,L.J.; Zhang,G.; Yu,L.; Zhang,Y.T.; Qin,R.L.; Tian,C.J.. |
| Although radical nephrectomy alone is widely accepted as the standard of care in localized treatment for renal cell carcinoma (RCC), it is not sufficient for the treatment of metastatic RCC (mRCC), which invariably leads to an unfavorable outcome despite the use of multiple therapies. Currently, sequential targeted agents are recommended for the management of mRCC, but the optimal drug sequence is still debated. This case was a 57-year-old man with clear-cell mRCC who received multiple therapies following his first operation in 2003 and has survived for over 10 years with a satisfactory quality of life. The treatments given included several surgeries, immunotherapy, and sequentially administered sorafenib, sunitinib, and everolimus regimens. In the course... |
| Tipo: Info:eu-repo/semantics/report |
Palavras-chave: Metastatic renal cell carcinoma; Sequential therapy; Targeted anticancer agents; Sorafenib; Sunitinib; Immunotherapy. |
| Ano: 2015 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000100034 |
| |
|
|
| Da-Costa,R.C.; Vieira,I.L.; Hunger,A.; Tamura,R.E.; Strauss,B.E.. |
| The immune stimulatory and anti-neoplastic functions of type I interferon have long been applied for the treatment of melanoma. However, the systemic application of high levels of this recombinant protein is often met with toxicity. An approach that provides localized, yet transient, production of type I interferon may overcome this limitation. We propose that the use of mesenchymal stem cells (MSCs) as delivery vehicles for the production of interferon-β (IFNβ) may be beneficial when applied together with our cancer gene therapy approach. In our previous studies, we have shown that adenovirus-mediated gene therapy with IFNβ was especially effective in combination with p19Arf gene transfer, resulting in immunogenic cell death. Here we showed that MSCs... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Gene therapy; Immunotherapy; Stem cell therapy; Adenovirus; P53; Interferon-β. |
| Ano: 2020 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2020000300601 |
| |
|
| |
|
| |
|
|
| Badaro,Roberto; Lobo,Iza; Nakatani,Maria; Muiños,Alvaro; M. Netto,Eduardo; Coler,Rhea N.; Reed,Steven G.. |
| Immunotherapy has been proposed as a method to treat mucosal leishmaniasis for many years, but the approach has been hampered by poor definition and variability of antigens used, and results have been inconclusive. We report here a case of antimonial-refractory mucosal leishmaniasis in a 45 year old male who was treated with three single injections (one per month) with a cocktail of four Leishmania recombinant antigens selected after documented hypo-responsiveness of the patient to these antigens, plus 50mg of GM-CSF as vaccine adjuvant. Three months after treatment, all lesions had resolved completely and the patient remains without relapse after two years. Side effects of the treatment included only moderate erythema and induration at the injection site... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Leishmaniasis; Immunotherapy; Mucosal leishmaniasis. |
| Ano: 2001 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702001000400008 |
| |
|
|
|
